l e t t e r s RNA exosomes are multi-subunit complexes conserved throughout evolution 1 and are emerging as the major cellular machinery for processing, surveillance and turnover of a diverse spectrum of coding and noncoding RNA substrates essential for viability 2 . By exome sequencing, we discovered recessive mutations in EXOSC3 (encoding exosome component 3) in four siblings with infantile spinal motor neuron disease, cerebellar atrophy, progressive microcephaly and profound global developmental delay, consistent with pontocerebellar hypoplasia type 1 (PCH1; MIM 607596) 3-6 . We identified mutations in EXOSC3 in an additional 8 of 12 families with PCH1. Morpholino knockdown of exosc3 in zebrafish embryos caused embryonic maldevelopment, resulting in small brain size and poor motility, reminiscent of human clinical features, and these defects were largely rescued by co-injection with wild-type but not mutant exosc3 mRNA. These findings represent the first example of an RNA exosome core component gene that is responsible for a human disease and further implicate dysregulation of RNA processing in cerebellar and spinal motor neuron maldevelopment and degeneration.
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Pontocerebellar hypoplasia (PCH) is a clinically and genetically heterogeneous group of autosomal recessive disorders characterized by cerebellar hypoplasia or atrophy, variable pontine atrophy and progressive microcephaly with global developmental delay 7 . PCH1 is a distinctive subtype of PCH, characterized by diffuse muscle wasting that is secondary to spinal cord anterior horn cell loss and cerebellar hypoplasia [3] [4] [5] [6] . Diagnosis with PCH1 is often delayed or never made because the combination of cerebellar and spinal motor neuron degeneration is not commonly recognized, and the presentation of diffuse weakness and devastating brain involvement is atypical of classical proximal spinal muscular atrophy (SMA) 8 . The literature contains only a handful of descriptions of case series 9-12 and reports of PCH1 (refs. [13] [14] [15] [16] [17] [18] [19] . The causative gene has not been identified in the majority of individuals with PCH1. Recessive mutations have been found in VRK1 (encoding vaccinia-related kinase 1) 20 , RARS2 (encoding mitochondrial arginyl-tRNA synthetase 2) 21 and TSEN54 (encoding tRNA splicing endonuclease 54) 22 in single individuals with PCH1. In PCH without SMA, TSEN54 mutations account for most cases of PCH2 and PCH4 (refs. 21, 23) , and RARS2 mutations have been found in two families with PCH6 (refs. 24, 25) .
Mutations in the RNA exosome component gene EXOSC3 cause pontocerebellar hypoplasia and spinal motor neuron degeneration l e t t e r s
We identified one family (family 1) in which four children were floppy at birth, had ocular motor apraxia, progressive muscle wasting, distal contractures, progressive microcephaly, growth retardation and global developmental delay, and never reached any motor milestone or spoke. Although normal in size at birth, in all four children, head circumference, height and weight dropped to below the 5th percentile by the age of 7-10 months. Magnetic resonance imaging (MRI) showed marked cerebellar atrophy with prominent sulci and decreased volume of folia ( Fig. 1a-d ) compared to age-and gendermatched normal individuals ( Fig. 1e-h) . In the affected individuals, the brainstem and the cerebral cortex appear normal in configuration but are small. Electromyography showed neurogenic motor changes in an 18-year-old subject (Fig. 1i) , which were exemplified by a single fast-firing (25 Hz) wave complex that was polyphasic (crossing the baseline multiple times) and unstable. The high-frequency firing in the absence of other complexes suggests a loss of axons, and unstable polyphasic units are manifestations of reinnervation in response to denervation. In a 9-year-old subject with PCH1, we observed borderline neurogenic motor changes ( Fig. 1j) , with a normal recruitment pattern but occasional large-amplitude motor unit action potentials (~4.5 mV) suggestive of reinnervation, compared to a normal individual ( Fig. 1k) , who showed multiple distinct wave complexes of normal amplitude (200-400 µV) that represent preserved motor axons without injury. Nerve conduction studies showed motor responses with severely reduced amplitude but normal sensory responses in the affected individuals ( Supplementary  Table 1 ). Furthermore, when the oldest child in family 1 died at age 18 years after a respiratory infection, the autopsy revealed a severe loss of cerebellar ( Fig. 1l,m) and spinal ( Fig. 1n) motor neurons compared to a control individual ( Fig. 1o-q) . These clinical features are most consistent with PCH1.
No PCH1-associated genes were known when this study began. We performed a genome scan of the four affected siblings, three healthy siblings and their parents, which narrowed the candidate regions to four subchromosomal loci with more than 100 candidate genes in total ( Supplementary Fig. 1 ). To identify the gene underlying PCH1, we captured the exomes from the four affected siblings using the SureSelect Human All Exon kit (Agilent Technology, G3362) and performed sequencing on a Genome Analyzer IIx (Illumina). This analysis yielded one candidate variant fulfilling the requirement of being a rare biallelic variant within the intervals identical by descent in all the affected individuals: g.9:37783990T>G in the EXOSC3 gene (c.395A>C, Ensembl ENST00000327304.4; encoding p.Asp132Ala, ENSP00000323046.4). We did not observe variants in VRK1, RARS2 or TSEN54 that have previously been reported in PCH1.
There are multiple alternatively spliced forms of EXOSC3, with the longest reading frame spanning 4 exons over 5,119 bases (NM_016042.2) and encoding a 275-amino acid protein, human exosome component 3 (EXOSC3), also known as the ribosomal RNA-processing protein 40 (RRP40) (NP_057126.2). EXOSC3 is a core component of the human RNA exosome complex (distinct from exosome vesicles) that is present in the cytoplasm and the nucleus and especially enriched in the nucleolus 26 . The N-terminal (NT) domain and putative RNA-binding S1 and KH domains are evolutionarily conserved ( Fig. 2) .
We confirmed genotype-phenotype co-segregation in family 1 by Sanger sequencing. To validate the association between EXOSC3 mutations b a Table 2 ) in the probands from 12 additional families with PCH1. Eight probands had recessive mutations in the gene ( Fig. 2 and Table 1 ). All available samples from the parents of the affected subjects were heterozygous for the mutations. None of the mutations were found in Turkish (n = 94), Czech (n = 96) or North American (principally of northern and western European ancestry) (n = 189) control individuals. A more recent review of databases, including the National Heart, Lung, and Blood Institute (NHLBI) Exome Sequencing Project, showed that the mutation encoding the p.Asp132Ala alteration has been observed in 6 of 4,870 exomes, with an estimated allele frequency of 0.0012. None of the other variants has been previously reported. The p.Asp132Ala alteration was present in seven of the nine mutationpositive families ( Fig. 2 and Table 1 ). This change affects a highly conserved amino-acid residue in the putative RNA-binding S1 domain; the crystal structure suggests that Asp132 may be important for intersubunit interaction within the exosome complex 27 . We genotyped the probands of families 1-3 who were homozygous for mutations causing the p.Asp132Ala alteration to find identical haplotypes in a 1-cM region flanking the mutation locus, which would suggest an ancestral origin for the mutation ( Supplementary Table 3 ).
We found three additional missense mutations. Two mutations, encoding p.Gly31Ala and p.Trp238Arg alterations, were present in family 4, with the parents being identified as carriers. The mutation encoding p.Gly31Ala was homozygous in the affected subject in family 9. Strictly conserved from yeast to humans, the Gly31 residue in the N-terminal domain seems to be involved in intersubunit interaction 27 , whereas the Trp238 residue is in the putative RNA-binding KH domain 27 .
In family 8, the affected subject harbored a mutation encoding p.Asp132Ala in trans with another missense mutation in the S1 domain, c.415G>C, encoding p.Ala139Pro ( Fig. 2 and Supplementary Note) .
We identified one frameshift mutation, a deletion spanning ten nucleotides in family 5, which is predicted to result in premature termination of the protein; the faulty transcript may be subject to nonsensemediated mRNA degradation. In silico analysis of the intronic mutation c.475-12A>G in family 6 suggested that it may introduce a new splice site just upstream of the normal splice acceptor for exon 3. RT-PCR in expression studies primarily showed skipping of exon 3 (shifting the reading frame) and evidence of aberrant splicing (which incorporated 11 nucleotides upstream of the normal splice site), with a minority of transcripts having normal splicing ( Supplementary Fig. 2  and Supplementary Table 2) .
The fact that biallelic missense, frameshift and splice-site mutations all led to the same clinical manifestations suggests that the alleles may be null or hypomorphic. Because all components of the exosome are essential for viability 1 , it is unlikely that individuals with PCH1 harbor biallelic null mutations; it is more likely that the missense mutations are hypomorphic, and the frameshift mutations could be null. In silico analyses predicted detrimental consequences from the missense mutations (Supplementary Table 4) . The standard marker for impaired exosome function has long been an abnormal accumulation of unprocessed rRNA 1 , which we did not observe in fibroblasts from the subject in family 1 (Supplementary Fig. 3 ), suggesting that the impact of the homozygous mutations in EXOSC3 encoding p.Asp132Ala may be more nuanced and subtle than a complete elimination of exosome function. npg l e t t e r s
To further examine the functional effects of the mutations, we knocked down endogenous exosc3 expression (NM_001029961.1) in zebrafish embryos by exosc3-specific antisense morpholino injection ( Fig. 3, Supplementary Fig. 4 and Supplementary Table 2) . Zebrafish embryos injected with antisense morpholinos directed against the start codon or the splice-donor site of exon 2 of exosc3 led to a dose-dependent phenotype of a short, curved spine and small brain with poor motility and even death by 3 days post fertilization (d.p.f.) compared to embryos injected with nonspecific, control morpholinos (Fig. 3a) .
The observation of shrunken or collapsed hindbrain in embryos injected with morpholinos targeting the splice-donor site prompted us to further investigate hindbrain-specific cells. Whole-mount in situ hybridization showed decreased expression of atoh1a (a marker specific for dorsal hindbrain progenitors) 28 by 1 d.p.f. in the upper and lower rhombic lips in embryos injected with morpholinos to the splice-donor site compared to the normal pattern of robust expression of atoh1a in hindbrain progenitors in the control-injected embryos 28 (Fig. 3b) . Whole-mount in situ hybridization further showed a lack of expression of pvalb7, which is specific for differentiated cerebellar Purkinje neurons 28 , by 3 d.p.f. in embryos injected with morpholinos to the splice-donor site compared to normal expression in distinct clusters of differentiated Purkinje cells in embryos injected with control morpholinos (Fig. 3b) .
The abnormal phenotype from exosc3-specific morpholino injection was largely rescued by co-injection with wild-type zebrafish exosc3 mRNA ( Fig. 3c and Supplementary Table 5 ), suggesting that the detrimental effects of the antisense morpholinos were specific to exosc3 knockdown. Co-injection with wild-type human EXOSC3 mRNA, which shares 67% identity with the zebrafish ortholog, was less effective in rescue. Co-injection with zebrafish or human mRNA containing the mutations was ineffective in rescue, suggesting that the mutations disrupted the normal function of EXOSC3 ( Fig. 3c and Supplementary Table 5 ). Survival data of embryos 1-3 d.p.f. are stratified and summarized (Supplementary Table 5 ).
We have discovered disease-causing mutations in a gene encoding the exosome component EXOSC3 leading to PCH1 with combined cerebellar and spinal motor neuron degeneration of infantile onset. There is clinical heterogeneity. Affected individuals in families 1 and 3 do not present with primary hypoventilation and have survived beyond infancy and early childhood, which is exceptionally unusual for classical PCH1 (refs. 7, 23) . Furthermore, in families 1 and 2, autopsy showed profound cerebellar atrophy and variable involvement of the pons and inferior olives, suggesting a degenerative process in addition to a developmental disorder. Additional studies will facilitate endophenotype stratification of PCH1. There is clear genetic heterogeneity in PCH1, as some affected individuals do not harbor mutations in any known PCH1-associated genes.
RNA exosomes are the principal enzymes that process and degrade RNA. The bulk of the human genome is transcribed to produce an extraordinary diversity of RNA 29 . The versatility and specificity of the exosome regulate the activity and maintain the fidelity of gene expression. Although exosomes are immunogenic in some individuals with polymyositis-scleroderma 30, 31 or chronic myelogenous leukemia 32, 33 , the findings in this report are the first to our knowledge to establish a pathogenic role for exosome core component mutations in human disease. Despite a growing effort to examine exosome function and subunit contribution, its substrates have not been fully characterized in humans or in lower animals, and the specific contribution of each component is incompletely understood. The discovery of naturally occurring mutations in exosome component genes provides a valuable opportunity to define subunit contribution to exosome function. Our findings suggest that normal function of the EXOSC3 component is essential for the survival of cerebellar and spinal motor neurons. Of note, RNA dysregulation is increasingly understood to be important in the etiology of motor and cerebellar degeneration. RNA processing defects are implicated in SMN1 deficiency in SMA 8 . Mutations in RNA-and/or DNA-binding proteins [34] [35] [36] [37] and pathogenic repeat expansions generating RNA that is likely toxic 38, 39 cause amyotrophic lateral sclerosis (ALS), an adultonset motor neuron disease. Gain of function of RNA from noncoding repeat expansions was recently proposed to cause combined spinocerebellar and brainstem motor neuron degeneration of late onset in SCA36 (ref. 40) . Dysregulation of tRNA processing underlies other subtypes of PCH 21, 23, 24 . Elucidation of the pathological mechanism underlying PCH1 may lead to new insights regarding RNA processing in the development and survival of cerebellar and spinal motor neurons. 
MeTHods
Methods and any associated references are available in the online version of the paper.
Note: Supplementary information is available in the online version of the paper.
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